	US 12,220,484 B2
	Stable formulations of lipids and liposomes
Heinrich Haas, Mainz (DE); and Isaac Hernan Esparza Borquez, Mainz (DE)
Assigned to BioNTech SE, Mainz (DE)
Filed by BioNTech SE, Mainz (DE)
Filed on Oct. 6, 2021, as Appl. No. 17/495,104.
Application 17/495,104 is a continuation of application No. 15/510,973, granted, now 11,173,120, previously published as PCT/EP2015/071344, filed on Sep. 17, 2015.
Prior Publication US 2022/0023212 A1, Jan. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/127 (2006.01); A61K 9/00 (2006.01); A61K 31/713 (2006.01)

CPC A61K 9/1272 (2013.01) [A61K 9/0019 (2013.01); A61K 31/713 (2013.01)]

20 Claims

1. An aqueous liposome dispersion comprising:

liposomes comprising 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE) and at least one cationic lipid selected from the group consisting of 1,2-di-O-octadecenyl-3-trimethylammoniumpropane (DOTMA) and 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP), and

at least one pH adjusting agent comprising an acid or an acidic buffer;

wherein:

a molar ratio of the at least one cationic lipid to DOPE is from about 1:4 to about 4:1; and

the pH of the aqueous liposome dispersion is from about 2 to about 5.5.